General Information

We are a biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. We develop our product candidates using our proprietary antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Our platform is based upon a breakthrough understanding of somatic hypermutation, the key biological process utilized to generate antibodies, which enables us to rapidly develop highly functional antibody drug candidates against emerging biological targets. Our most advanced, wholly-owned programs, ANB020 and ANB019, are being developed to treat severe inflammatory disorders with unmet medical need. Additionally, we have entered into multiple collaborations from which we expect four programs will enter the clinic in the next 18 months. Our collaborations include an immuno-oncology-focused collaboration with TESARO and an inflammation-focused collaboration with Celgene. Through August 31, 2015, we have received significant, non-dilutive funding of $48.7 million from our collaborators

Employees: 49
Founded: 2005
Contact Information
Address 10421 Pacific Center Court, Suite 200, San Diego, CA 92121, US
Phone Number (858) 362-6295
Web Address
View Prospectus: AnaptysBio
Financial Information
Market Cap $287.4mil
Revenues $18.0 mil (last 12 months)
Net Income $-3.5 mil (last 12 months)
IPO Profile
Symbol ANAB
Exchange NASDAQ
Shares (millions): 5.0
Price range $15.00 - $15.00
Est. $ Volume $75.0 mil
Manager / Joint Managers Credit Suisse/ Stifel
CO-Managers JMP Securities/ Wedbush PacGrow
Expected To Trade: 1/26/2017
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change